Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsFRA:3ZO0 35 Buyback Yield % is -113.29 as of Aug. 03, 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, Acurx Pharmaceuticals ranks worse than 90.88% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Acurx Pharmaceuticals Buyback Yield % Related Terms
Acurx Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Acurx Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3ZO0 vs KAPA, PULM, ADIL: Buyback Yield % Comparison
For the Biotechnology subindustry, Acurx Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acurx Pharmaceuticals (FRA:3ZO0) has a Buyback Yield % of -113.29 as of Aug. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Acurx Pharmaceuticals and its competitors. According to the industry distribution chart, Acurx Pharmaceuticals ranks #668 out of 735 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Acurx Pharmaceuticals' Buyback Yield % too high?
Acurx Pharmaceuticals' current Buyback Yield % is -113.29. Based on the distribution chart, Acurx Pharmaceuticals ranks #668 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Buyback Yield % compare to KAPA and PULM?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #668 out of 735 companies for Buyback Yield %. This places Acurx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Acurx Pharmaceuticals and its competitors. Acurx Pharmaceuticals's current Buyback Yield % is -113.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Buyback Yield % of -113.29. The current Buyback Yield % is -113.29. Acurx Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Buyback Yield % is -113.29 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
35GF Score
Get the complete analysis for FRA:3ZO0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3ZO0 has been successfully added to your 
